Pearl Therapeutics to be Acquired by AstraZeneca for up to $1.15 Billion
10. Juni 2013 02:10 ET
|
Pearl Therapeutics
Redwood City, CA, June 10, 2013 (GLOBE NEWSWIRE) -- Pearl Therapeutics
Inc. today announced that it has entered into a definitive
merger agreement under which the Company will be acquired...
Pearl Therapeutics Presents Dose-Ranging, Efficacy and Safety Results of PT003 as well as Components, PT001 and PT005 at American Thoracic Society Meeting
17. Mai 2013 08:00 ET
|
Pearl Therapeutics
REDWOOD CITY, CALIF, May 17, 2013 (GLOBE NEWSWIRE) -- Pearl Therapeutics Inc. today announced that the Company would
be presenting four posters at the upcoming annual meeting of the
American Thoracic...
Pearl Therapeutics Initiates PT003 Phase 3 Program for the Treatment of Individuals with Moderate-to-Severe COPD
13. Mai 2013 17:28 ET
|
Pearl Therapeutics
Redwood City, CA, May 13, 2013 (GLOBE NEWSWIRE) -- Pearl Therapeutics Inc. today announced the initiation of
PINNACLE, a global Phase 3 program of PT003, the Company's
fixed-dose combination of...
Pearl Therapeutics Receives Award for Innovative Co-Suspension Technology
14. März 2013 08:00 ET
|
Pearl Therapeutics
REDWOOD CITY, CALIF, March 14, 2013 (GLOBE NEWSWIRE) -- Pearl Therapeutics Inc. today announced their receipt of the
2013 Drug Delivery Partnerships™ (DDP) Innovation Award for the
Company's...
Pearl Therapeutics Strengthens its Organization by Hiring Dr. Michael Riebe, an Industry Veteran in Respiratory Product Development
17. Januar 2013 08:00 ET
|
Pearl Therapeutics
REDWOOD CITY, CALIF, Jan. 17, 2013 (GLOBE NEWSWIRE) -- Pearl Therapeutics Inc. today announced that Michael
Riebe, Ph.D. has joined Pearl Therapeutics as vice president,
pharmaceutical development and...
Pearl Therapeutics to Present at J.P. Morgan Healthcare Conference
04. Januar 2013 08:00 ET
|
Pearl Therapeutics
REDWOOD CITY, CALIF, Jan. 4, 2013 (GLOBE NEWSWIRE) -- Pearl Therapeutics Inc. today announced that Chuck
Bramlage, the Company's president and CEO will be providing a
corporate and clinical update at...
Pearl Therapeutics Issued U.S. Patent on Co-Suspension Formulation Technology
05. Dezember 2012 08:00 ET
|
Pearl Therapeutics
REDWOOD CITY, CALIF., Dec. 5, 2012 (GLOBE NEWSWIRE) -- Pearl Therapeutics Inc. today announced that the U.S. Patent and
Trademark Office has issued a patent on its novel co-suspension
formulation...
Pearl Therapeutics Raises $65 Million Series D to Start PT003 Phase 3
13. November 2012 07:30 ET
|
Pearl Therapeutics
REDWOOD CITY, CALIF, Nov. 13, 2012 (GLOBE NEWSWIRE) -- Pearl Therapeutics Inc. today announced a $65 million
Series D financing raised from current investors. 5AM
Ventures, Clarus Ventures and...